- In February 2024, Viatris and Idorsia have entered a major North America research and development collaboration to advance innovative therapies across multiple therapeutic areas. This partnership leverages Idorsia’s drug discovery expertise and Viatris’ North America reach, accelerating the development of groundbreaking treatments and expanding both companies’ pipelines, reinforcing their commitment to addressing unmet medical needs worldwide
- In February 2021, Fresenius Kabi has expanded its facilities in Austria, strengthening its production capabilities and innovation in pharmaceuticals and medical technologies. This expansion enhances manufacturing efficiency, ensures a steady supply of critical care products, and supports research advancements. By increasing capacity and operational excellence, the company reinforces its market presence and meets the growing North America demand for healthcare solutions
Frequently Asked Questions
Companies such as Pfizer Inc. (U.S.), Teva Pharmaceuticals U.S., Inc. (U.S.), Fresenius SE & Co. KGaA (Fresenius Kabi AG) (Germany), Viatris Inc. (U.S.), Amneal Pharmaceuticals LLC. (U.S.) are the major companies in North America traumatic brain injury treatment market.
In February 2024, Viatris and Idorsia have entered a major North America research and development collaboration to advance innovative therapies across multiple therapeutic areas. This partnership leverages Idorsia’s drug discovery expertise and Viatris’ North America reach, accelerating the development of groundbreaking treatments and expanding both companies’ pipelines, reinforcing their commitment to addressing unmet medical needs worldwide
The countries covered in North America traumatic brain injury treatment market are U.S., Canada, and Mexico.
